EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study

Neoadjuvantes Pembrolizumab plus Chemotherapie/adjuvantes Pembrolizumab bei frühem triple-negativem Brustkrebs: Lebensqualitätsdaten aus der randomisierten KEYNOTE-522-Studie

Rebecca Dent iD, Javier Cortés, Lajos Pusztai iD, Heather McArthur, Sherko Kümmel, Jonas Bergh iD, Carsten Denkert iD, Yeon Hee Park, Rina Hui iD, Nadia Harbeck, Masato Takahashi iD, Michael Untch und 8 weitere

JNCI: Journal of the National Cancer Institute · 01.10.2024 · 116 (10) · 1654-1663

DOI: 10.1093/jnci/djae129 ↗

Auf einen Blick

In KEYNOTE-522 zeigten sich zwischen Pembrolizumab plus Chemotherapie und Placebo plus Chemotherapie keine wesentlichen Unterschiede in den patientenberichteten Endpunkten bei frühem TNBC.

Fragestellung

Wie unterscheiden sich patientenberichtete Lebensqualitätswerte unter neoadjuvantem Pembrolizumab plus Chemotherapie mit anschließender adjuvanter Pembrolizumab-Gabe im Vergleich zu Placebo plus Chemotherapie bei frühem TNBC?

Methode

Randomisierte Studie KEYNOTE-522; 2:1-Zuteilung zu Pembrolizumab oder Placebo plus Chemotherapie neoadjuvant, danach adjuvant bis zu 9 Zyklen; PROs mit EORTC QLQ-C30 und QLQ-BR23.

Ergebnisse

Neoadjuvant betrugen die LS-Mittelwertdifferenzen bis Woche 21 für GHS/QoL −1,04 (95 %-KI −3,46 bis 1,38), emotionale Funktion −0,69 (95 %-KI −3,13 bis 1,75) und körperliche Funktion −2,85 (95 %-KI −5,11 bis −0,60). Adjuvant bis Woche 24: −0,41, −0,60 und −1,57.

Schlussfolgerung der Autor:innen

Es wurden keine wesentlichen Unterschiede in den PRO-Bewertungen zwischen neoadjuvantem Pembrolizumab plus Chemotherapie mit adjuvantem Pembrolizumab und Placebo plus Chemotherapie beobachtet.

Kernaussagen

  • Keine wesentlichen PRO-Unterschiede zwischen den Gruppen
  • Neoadjuvant: GHS/QoL −1,04; körperliche Funktion −2,85
  • Adjuvant: GHS/QoL −0,41; emotionale Funktion −0,60

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 24.06.2024. Verfasst von Rebecca Dent und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Singapore and Duke-National University of Singapore (NUS) Medical School, Division of Medical Oncology, Singapore, Singapore. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Quality of Life, Triple Negative Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, AstraZeneca, Merck & Co., Inc..

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab plus chemotherapy and then adjuvant pembrolizumab significantly improved pathological complete response and event-free survival vs neoadjuvant chemotherapy in early-stage triple-negative breast cancer (TNBC). We report patient-reported outcomes (PROs) from KEYNOTE-522.

Methods

Patients were randomized 2:1 to neoadjuvant pembrolizumab 200 mg or placebo every 3 weeks, plus 4 cycles of paclitaxel plus carboplatin and then 4 cycles of doxorubicin (or epirubicin) plus cyclophosphamide. After surgery, patients received adjuvant pembrolizumab or placebo for up to 9 cycles. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23) were prespecified secondary objectives. Between-group differences in least squares (LS) mean change from baseline (day 1 of cycle 1 in both neoadjuvant and adjuvant phases) to the prespecified latest time point with at least 60% completion and at least 80% compliance were assessed using a longitudinal model (no alpha error assigned).

Results

Week 21 (neoadjuvant phase) and week 24 (adjuvant phase) were the latest time points at which completion/compliance rates were ≥60%/80%. In the neoadjuvant phase, between-group differences (pembrolizumab plus chemotherapy [n = 762] vs placebo plus chemotherapy [n = 383]) in LS mean change from baseline to week 21 in QLQ-C30 global health status/quality of life (GHS/QoL), emotional functioning, and physical functioning were −1.04 (95% confidence interval = −3.46 to 1.38), −0.69 (95% CI = −3.13 to 1.75), and −2.85 (95% CI = −5.11 to −0.60), respectively. In the adjuvant phase, between-group differences (pembrolizumab [n = 539] vs placebo [n = 308]) in LS mean change from baseline to week 24 were −0.41 (95% CI = −2.60 to 1.77), −0.60 (95% CI = −2.99 to 1.79), and −1.57 (95% CI = −3.36 to 0.21).

Conclusions

No substantial differences in PRO assessments were observed between neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab vs neoadjuvant placebo plus chemotherapy in early-stage TNBC.

Trial registration

ClinicalTrials.gov, NCT03036488.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedQuality of LifeTriple Negative Breast NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedChemotherapy, AdjuvantAgedAdultPaclitaxelCyclophosphamideCarboplatinNeoplasm StagingPatient Reported Outcome MeasuresEpirubicinDoxorubicin

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedPaclitaxelCyclophosphamideCarboplatinEpirubicinDoxorubicin

Autor:innen und Institutionen

  • National Cancer Center Singapore and Duke-National University of Singapore (NUS) Medical School, Division of Medical Oncology, Singapore, Singapore.
  • Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
  • International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
  • Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.
  • IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana, Madrid, Spain.
  • Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.

ORCID-Profile: Rebecca Dent, Lajos Pusztai, Jonas Bergh, Carsten Denkert, Rina Hui, Masato Takahashi, Peter A Fasching, Fatima Cardoso

Förderung

  • NCATS NIH HHS
  • AstraZeneca
  • Merck & Co., Inc.
  • Merck Sharp & Dohme LLC

Zitieren

APA

Dent, R., Cortés, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Untch, M., Fasching, P. A., Cardoso, F., Haiderali, A., Jia, L., Nguyen, A. M., Pan, W., O'Shaughnessy, J., & Schmid, P. (2024). Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. JNCI: Journal of the National Cancer Institute, 116(10), 1654-1663. https://doi.org/10.1093/jnci/djae129

Vancouver

Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. JNCI: Journal of the National Cancer Institute. 2024;116(10):1654-1663. doi:10.1093/jnci/djae129

BibTeX
@article{Dent2024,
  author = {Dent, Rebecca and Cortés, Javier and Pusztai, Lajos and McArthur, Heather and Kümmel, Sherko and Bergh, Jonas and Denkert, Carsten and Park, Yeon Hee and Hui, Rina and Harbeck, Nadia and Takahashi, Masato and Untch, Michael and Fasching, Peter A and Cardoso, Fatima and Haiderali, Amin and Jia, Liyi and Nguyen, Allison Martin and Pan, Wilbur and O'Shaughnessy, Joyce and Schmid, Peter},
  title = {Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  volume = {116},
  number = {10},
  pages = {1654--1663},
  doi = {10.1093/jnci/djae129}
}
Kostenlos starten →